Evidence map›Paper›PMID 37891598›Full record

ArticleJournal of nanobiotechnology2023

TiO

Xupeng Mu, Kebang Hu, Anhui Wei, Jinping Bai, Li Feng, Jinlan Jiang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Chiral Titanium Dioxide Nanoparticles Induce Breast Cancer Lung Metastasis.Advanced materials (Deerfield Beach, Fla.) · 2026
    Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Xupeng Mu *Scientifc Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Kebang Hu *Department of Urology, Lequn Branch, The First Hospital of Jilin University, Changchun, 130031, China.
Anhui WeiDepartment of Regenerative Medicine, College of Pharmacy, Jilin University, Changchun, 130021, China.
Jinping BaiDepartment of Chronic Disease, Jilin Province FAW General Hospital, Changchun, 130013, China.
Li FengDepartment of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China. f_l@jlu.edu.cn.
Jinlan JiangScientifc Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, China. jiangjinlan@jlu.edu.cn.
Jilin University · CNFirst Hospital of Jilin University · CNJilin Province Tumor Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of nanotechnology has provided numerous possibilities for the diagnosis and treatment of cancer. Paradoxically, some in vivo experimental studies have also shown that nanoparticles (NPs) could promote tumor progression, but the specific mechanism is not yet clear. Primary tumors can release extracellular vesicles (EVs) which can promote the inoculation and growth of tumor cells that have metastasized to distant organs. So, whether nanomaterials can promote tumor progression through tumor-derived EVs deserves further research. Here, we showed that TiO

Indexed as

Extracellular VesiclesMicroRNAsNanoparticlesNeoplasmsEndothelial CellsHumansTitaniumMicroRNAsTitaniumtitanium dioxideAngiogenesisExtracellular vesiclesNanoparticlesTumor metastasisVascular permeability

Identifiers

PMID37891598
PMCPMC10604521
OpenAlexW4387974351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.